Simultaneous Publication in the Era of Rapid Dissemination: Why Strategic Collaboration Matters

An insight by Claudia Piano (EVP, BU Lead, ApotheCom) and Donna Kelley (Senior Director, Client Services ApotheCom)

Our recent parallel session at the 2026 ISMPP Annual Meeting in Washington, DC, developed in collaboration with both a current and former client, reflects this year’s MedComms Day theme: Pride in Profession. The session highlighted how successful simultaneous publication strategies are built on scientific rigor, strategic partnership, and cross-functional collaboration—demonstrating the critical role publication professionals play in accelerating dissemination of impactful clinical data. Our team’s longstanding client partnerships and shared commitment to excellence have enabled us to develop deep expertise in delivering simultaneous publications in highly competitive, fast-moving environments.

The rationale for simultaneous publication is compelling. Congress presentations often provide only a high-level overview of clinical data, while full manuscripts offer the detailed methodology and interpretation necessary for informed evaluation. Publishing both simultaneously ensures healthcare professionals, researchers, policymakers, and the public can access the complete scientific story at the moment of disclosure while maximizing attention generated during major scientific meetings.

The presentation emphasized that simultaneous publication could amplify visibility and engagement. Case studies comparing simultaneous versus non-simultaneous publication strategies demonstrated higher Altmetric attention scores for simultaneously published studies, suggesting greater online discussion, media coverage, and scientific engagement. However, publication timing alone does not drive impact. Clinical relevance, unmet need, and the strength of the scientific narrative remain the dominant factors influencing attention and adoption.

A compelling example presented was the DESTINY clinical trial publication program. Through close coordination among sponsors, publication teams, authors, journals, and congress organizers, pivotal oncology studies were simultaneously presented at major congresses and published in high-impact journals such as The New England Journal of Medicine. These efforts contributed to rapid awareness, accelerated clinical adoption, and inclusion in treatment guidelines.

Achieving successful simultaneous publication requires exceptional planning and collaboration. The session highlighted recurring challenges, including compressed timelines, resource constraints, evolving data availability, peer-review demands, and the complexity of managing multiple stakeholders across global teams. Early scenario planning and proactive communication are essential to navigating these pressures.

Stakeholder commitment plays a critical role throughout the process. Successful strategies depend on strong partnerships among pharmaceutical companies, publication agencies, medical writers, and cross-functional teams. Aligning expectations early around timelines, congress targets, journal selection, data readiness, and regulatory considerations help minimize delays and enable rapid decision-making when unexpected issues arise.

Our presentation reinforced the fact that flexibility is essential. Even with meticulous planning, teams must prepare for setbacks such as journal rejection, delayed data availability, or changing congress requirements. Ultimately, simultaneous publication is best viewed as an amplifier rather than the sole driver of impact. When paired with compelling clinical data and effective collaboration, it can significantly elevate scientific visibility and accelerate the translation of research into clinical practice.Top of Form

To learn how ApotheCom can help maximize the visibility and impact of your clinical data through strategic simultaneous publication planning, connect with our team.